BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

NEWS: BDSI Completes Acquisition of ELYXYB Learn More >
BDSI
BDSI
INSPIRING SOLUTIONS FOR BETTER HEALTH
BDSI advances novel therapies designed to improve the lives of people living with serious and debilitating chronic conditions
Hear from the Experts

Dr. Jessica Ailani and Dr. Peter McAllister share their views on ELYXYB™ (celecoxib) oral solution, the first and only FDA-approved treatment of its kind.

Watch now

Purpose

BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company working to deliver innovative therapies for individuals living with serious and debilitating chronic conditions.

Learn more

Patients

BDSI subscribes to a patients-first philosophy. We are a dynamic team driven by the knowledge that the work we do can have a positive impact on patients, their caretakers, and loved ones.

Learn more

Products

BDSI offers a diverse portfolio of solutions for the treatment of serious and debilitating chronic conditions, including unique therapeutic innovations like a buccal film technology designed to help optimize drug delivery.

Learn more

Recent BDSI News

January 20, 2022

Total 2021 Net Revenue expected in the range of $165 - $167 million , as compared to previous guidance of $162-$167 million BELBUCA 2021 Net Sales expected to be in the range of $147 - $148 million , as compared to previous guidance of $144-$148 million 2021 EBITDA expected to be in the $40 - $45

Read more
December 20, 2021

RALEIGH, N.C. , Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that the U.S.

Read more
November 3, 2021

Total Net Revenue of $41.1 Million , an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07 , EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
January 28, 2022BDSI $3.605/ - -1.5%
Data provided by Nasdaq. Minimum 15 minutes delayed.